News

XenDex $XDX Presale: 20% Sold in a Day, Analysts Bullish!

XenDex $XDX Presale: 20% Sold in a Day, Analysts Bullish!

XenDex's Exciting Presale Achievement

Recently, the XenDex team revealed an impressive milestone: their token presale saw over 20% of the $XDX allocation filled within just 24 hours of launch. This remarkable uptake has stirred excitement within the crypto community, positioning XenDex as one of the hottest projects on the XRP Ledger. Investors have quickly recognized the opportunity that XenDex presents, sparking predictions that the presale might sell out completely in less than 10 days.

Why Investors Are Joining the XenDex Revolution

As the first decentralized exchange (DEX) powered by AI on the XRP Ledger, XenDex is not just another platform—it's a game changer. It introduces a user-friendly experience that welcomes both seasoned DeFi enthusiasts and newcomers. Through innovative features such as copy trading, non-custodial lending, and cross-chain functionality, it provides real utility that appeals to a broad audience.

Details of the $XDX Presale

During this presale, the minimum purchase requirement is set at 150 XRP, which translates to approximately 1,500 XDX tokens. The soft cap for this initiative has been set at 30,000 XRP, providing a clear goal for investors who are eager to join this vibrant project.

Unique Features Setting XenDex Apart

Investors are keen on XenDex due to several standout features:

  • Non-Custodial Lending & Borrowing: Users can lend or borrow XRP native tokens and $XDX to earn rewards.
  • AI-Powered Copy Trading: This revolutionary feature allows users to mirror successful trading strategies, making it easier to navigate the crypto market.
  • Cross-Chain Trading: Users can trade their XRP tokens seamlessly across various blockchain networks, including Solana and BNB.

The growing interest in XenDex is palpable, with many joining its active communities on platforms like Telegram and X (Twitter). The pressing demand is evident, with the remaining $XDX tokens likely to deplete quickly if the momentum continues.

The Future of DeFi on the XRP Ledger

Crypto analysts are optimistic; if demand keeps rising, the entire $XDX supply could vanish within a few days. The benefits for early participants are significant, including secure pricing, potential future rewards, staking opportunities, and governance rights that stakeholders will enjoy as the platform evolves.

Now is the time to get involved in the future of DeFi with XenDex. The token presale presents a unique opportunity for investors to secure their place in a visionary project that’s redefining what’s possible on the XRP Ledger.

Frequently Asked Questions

What is the XenDex $XDX presale?

The XenDex $XDX presale is a fundraising initiative where investors can purchase $XDX tokens before they are publicly available.

How much of the presale was filled in the first 24 hours?

Over 20% of the $XDX allocation was sold within the first 24 hours of the presale launch.

What are the unique features of the XenDex platform?

XenDex offers non-custodial lending & borrowing, AI-powered copy trading, and cross-chain trading capabilities.

What is the minimum purchase requirement for the presale?

The minimum purchase to participate in the presale is set at 150 XRP.

How can I buy $XDX tokens?

Interested participants can buy $XDX tokens during the presale by visiting the XenDex website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 176

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Monster Energy Unleashes Gaming Frenzy at Cosm L.A. Event

Updated Category News Views 144

Where Energy Drinks and Digital Reality Collide Monster Energy sure knows how to throw a party, especially when it hinges on something as electrifying as Call of Duty: Modern Warfare 4. Imagine this: Cosm Los Angeles is decked out with a massive 87-foot LED dome, and every gamer, celeb, and influencer ready to dive right in. You can't make this stuff up. They've mashed...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 295

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 62

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Love Business Group Helps SMEs Navigate Broadband Choices

Updated Category News Views 118

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 175

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Tennessee's Bold Lung Cancer Trial Signals Innovation

Updated Category News Views 113

The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 280

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Miranda Lambert Lights Up Red Kettle Campaign

Updated Category News Views 178

A Star-Studded Start to the Season of Giving Miranda Lambert is set to dazzle audiences yet again, and if there's one thing this country music titan knows, it's how to crank up the heartstrings while fanning the flames of generosity. She'll take to the stage at AT&T Stadium this Thanksgiving during the Dallas Cowboys game, bringing a powerful performance to light up the...

Continue Reading

Top 5 Most Recently Viewed Articles

QYOU Media Announces Major Financial Update and Live Call

Updated Category News Views 126

QYOU Media to Host Financial Results Call Join Us for a Live Shareholder Session QYOU Media Inc. (TSXV: QYOU) (OTCQB: QYOUF) is gearing up to share its financial performance for the fiscal third quarter. The results will be disclosed before market opening at 8 AM EST. The much-anticipated live conference call is scheduled for a few hours later, at 11:00 AM Eastern...

Continue Reading
Breakthrough Research on Dupuytren Contracture by Endo, Inc.

Updated Category News Views 323

Endo Presents Groundbreaking Research on Dupuytren Contracture Endo, Inc. (OTCQX: NDOI) recently showcased vital research regarding the use of XIAFLEX (collagenase clostridium histolyticum or CCH) for treating recurrent Dupuytren contracture. This presentation took place during an esteemed congress in March 2025, hosted by leading societies in hand surgery and therapy....

Continue Reading
Abbott's Volt PFA System Shows Promising Long-Term Benefits

Updated Category News Views 366

Long-Term Efficacy of Abbott's Volt PFA System Abbott has revealed encouraging findings from its Volt CE Mark Study, which indicates strong safety and effectiveness outcomes for patients undergoing pulsed field ablation (PFA) therapy using the Volt™ PFA System. With results tracking up to 12 months, the study underscores the therapy's potential benefits for individuals...

Continue Reading
Chemours Sets Third Quarter Earnings Call and Webcast Schedule

Updated Category News Views 55

Chemours Company Announces Upcoming Financial Results The Chemours Company, recognized as a global leader in industrial and specialty chemicals, has announced its plans for the third quarter 2024 financial results. The company, trading under the ticker NYSE: CC, is dedicated to informing its stakeholders with timely and relevant updates. Details on the Earnings Release...

Continue Reading
Michigan's Agritourism Flourishes with Culinary Experiences

Updated Category News Views 175

Pure Michigan Enhances Culinary Tourism Efforts Recent spotlight on Michigan's culinary landscape has taken center stage with the nomination of The Cook's House for a prestigious award, showcasing co-chefs Jennifer Blakeslee and Eric Patterson. The initiative, led by Pure Michigan, aims to elevate not just the restaurants but also the state's agricultural significance,...

Continue Reading